Another Small Step Forward in ALS Treatment
Another Small Step Forward in ALS Treatment
Source: Lai EC, et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS: A placebo-controlled study. Neurology 1997;49:1621-1630.
Als is slowly yielding its fatal path to the tenacious onslaught of systemic drugs. Among 266 patients with ALS randomized in a nine-month, double-blind, placebo-controlled trial using low- (0.05 mg/kg/d s/c qd) or high-dose (0.05 mg/kg/d s/c bid) recombinant human insulin-like growth factor-I (rhIGF-I), functional decline was 26% slower in the high-dose group than in those receiving placebo (P = 0.01). Quality of life, as assessed by the Sickness Impact Profile (SIP), declined more slowly in the high-dose group, and patients in the low-dose group tended toward a similar benefit without reaching significance, suggesting the presence of a dose- dependent effect. Significant adverse experiences were similar in the three groups, most frequently including injection site complaints of pain, inflammation, and bleeding. rhIGF-I has yet to be shown to prolong survival, but, perhaps more importantly, it is the first agent to slow symptom progression and, thus, will likely play a role in the treatment of ALS. -mr
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.